LEVETIRACETAM IN SODIUM CHLORIDE
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Levetiracetam binds to synaptic vesicle glycoprotein 2A (SV2A), modulating neurotransmitter release and reducing neuronal hyperexcitability.
| Metabolism | Levetiracetam is primarily eliminated renally; approximately 24% undergoes metabolism by hydrolysis of the acetamide group, not dependent on CYP450 enzymes. |
| Excretion | 66% renal (unchanged), 27% as inactive metabolite (UCB L057) via renal; <1% fecal |
| Half-life | 6-8 hours in adults; prolonged in elderly (10-11 h) and renal impairment (up to 25 h in ESRD) |
| Protein binding | <10% (negligible); not bound to albumin or alpha-1-acid glycoprotein |
| Volume of Distribution | 0.5-0.7 L/kg; approximates total body water, indicating extensive distribution into tissues and CNS |
| Bioavailability | IV: 100%; Oral: 100% (rapid and complete absorption) |
| Onset of Action | IV: within 5-15 minutes after infusion; Oral: 1-2 hours |
| Duration of Action | IV: 4-6 hours (seizure protection); Oral: 6-8 hours (steady-state trough concentrations maintained for twice-daily dosing) |
500-1500 mg IV every 12 hours; initial dose 1000 mg/day, titrate by 1000 mg/day every 2 weeks up to 3000 mg/day.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl >80 mL/min: 500-1500 mg every 12h; CrCl 50-80: 500-1000 mg every 12h; CrCl 30-50: 250-750 mg every 12h; CrCl <30: 250-500 mg every 12h; ESRD: 500-1000 mg every 24h with 250-500 mg supplement post-dialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Severe impairment (Child-Pugh C): reduce maintenance dose by 50%. |
| Pediatric use | 1 month to <6 months: 7 mg/kg/dose IV every 12h; 6 months to <4 years: 10 mg/kg/dose IV every 12h; 4 to <16 years: 10 mg/kg/dose IV every 12h up to 30 mg/kg/day. Maximum 3000 mg/day. |
| Geriatric use | Initiate at 500 mg twice daily, titrate slowly due to age-related renal function decline; adjust dose per creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Levetiracetam is excreted into human breast milk with a milk-to-plasma (M/P) ratio of approximately 1.0. Infant exposure is estimated to be 1-2% of the maternal weight-adjusted dose. No adverse effects have been reported in breastfed infants, but caution is recommended. |
| Teratogenic Risk | Levetiracetam is associated with an increased risk of major congenital malformations, particularly neural tube defects, when used during the first trimester. Exposure in the second and third trimesters may lead to fetal growth restriction and neurodevelopmental effects. The risk appears dose-dependent. |
■ FDA Black Box Warning
No FDA black box warnings.
| Common Effects | fluid replacement |
| Serious Effects |
["Hypersensitivity to levetiracetam or any component of the formulation"]
| Precautions | ["Behavioral and psychiatric symptoms: aggression, agitation, anger, anxiety, depression, mood swings, psychosis, suicidal ideation","Somnolence and fatigue","Serious dermatological reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis)","Hematologic abnormalities (e.g., decreased white blood cell counts)","Hypersensitivity reactions including angioedema","Renal impairment requires dose adjustment"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum levels of levetiracetam due to decreased drug concentrations during pregnancy. Perform fetal ultrasound for neural tube defects and growth. Consider neurodevelopmental follow-up for the child after birth. |
| Fertility Effects | Levetiracetam does not appear to have significant adverse effects on human fertility. Animal studies show no impairment of fertility at clinically relevant doses. |